Titre:
  • Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
Auteur:Cortes, Javier; Vahdat, L.; Blum, J.; Twelves, Chris J; Campone, M.; Roche, Henri; Bachelot, Thomas; Awada, Ahmad; Paridaens, R.; Goncalves, A.; Shuster, D.; Wanders, Jantien; Fang, F.; Gurnani, R.; Richmond, E.; Cole, Patricia E; Ashworth, Simon; Allison, M.
Informations sur la publication:Journal of clinical oncology, 28, 25, page (3922-3928)
Statut de publication:Publié, 2010-09
Sujet CREF:Cancérologie
MeSH keywords:Adult
Aged
Aged, 80 and over
Antineoplastic Agents -- adverse effects -- therapeutic use
Breast Neoplasms -- drug therapy -- pathology
Disease-Free Survival
Drug Administration Schedule
Ethers, Cyclic
Female
Furans -- adverse effects -- therapeutic use
Humans
Ketones -- adverse effects -- therapeutic use
Middle Aged
Peripheral Nervous System Diseases -- chemically induced
Retreatment
Note générale:Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langue:Anglais
Identificateurs:urn:issn:0732-183X
info:doi/10.1200/JCO.2009.25.8467
info:pii/JCO.2009.25.8467
info:pmid/20679609